If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-06. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In 2025, Willis underwent keyhole heart surgery after medical investigations revealed that she had a congenital hole in her heart which she had been unaware of for 48 years. The condition was discovered following routine checks and further investigation after an MRI scan identified an enlargement in her heart. Willis underwent the procedure at the Royal Brompton Hospital and later publicly thanked the medical staff who treated her.
== Awards == German Innovation Award. Excellence in Business to Business – Pharmaceuticals, Winner 2019 German Innovation Award, Fortibone January 2020 Nutra Ingredients Awards. Ingredient of the Year: Healthy Ageing – Fortibone, GELITA – 2018, Winner 2018, January 2020 Life PR Award: German Innovation Award in gold for innovative detergent additive Novotec CB800, June 6, 2018 Nutraceuticals World: Top 100 Innovative Companies in Germany, Category "Innovative Processes" Cannes Corporate Media & TV Awards 2016: Four Dolphins for the company Video "You can see". Gold in category corporate videos and silver in the categories marketing films – B2B, information films and visitors films German Brand Award for successful brand management in the category "Industry Excellence in Branding", 2016 "Intermedia-globe Award" in gold, World Media Festival June 22, 2016 Frost & Sullivan Award, "European Health Ingredient of the Year" – 2008 New Hope, "GELITA Wins Frost & Sullivan Award European Health Ingredient of the Year 2008"
== Gene == The COL3A1 gene is located on the long (q) arm of chromosome 2 at 2q32.2, between positions 188974372 and 189012745. The gene has 51 exons and is approximately 40 kbp long. The COL3A1 gene is in tail-to-tail orientation with a gene for another fibrillar collagen, namely COL5A2. Two transcripts are generated from the gene using different polyadenylation sites. Although alternatively spliced transcripts have been detected for this gene, they are the result of mutations; these mutations alter RNA splicing, often leading to the exclusion of an exon or use of cryptic splice sites. The resulting defective protein is the cause of a severe, rare disease, the vascular type of Ehlers-Danlos syndrome (vEDS). These studies have also provided important information about RNA splicing mechanisms in multi-exon genes.
These are available salted or in brine and they are primarily used by medium to large sausage makers who do not want to pay the additional cost for the tubed casing and do not have automatic sausage stuffing and linking machines (which require tubed casings to operate efficiently). These are available in all diameters and in lengths greater than 2 meters. Beef casings are primarily available only salted or in brine. They are measured in sets, not hanks, and the length is 32 meters; this is for beef "rounds" and "middles" only, as beef bung caps are only about 1 meter in length.
=== Availability === Lemborexant is marketed in the United States, Canada, Australia, and Japan. It is not approved by the European Medicines Agency (EMA) for use in the European Union or by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Sources: en.wikipedia.org
Potentiation of anticholinergic effects caused by zotepine Decreasing efficacy of cisapride Procainamide (potentiation of vagus nerve activity inhibition, thereby causing a positive chronotropic effect and, in turn, tachycardia) calcium channel blockers
== Further reading == Buckley, C.P. "Material Failure", Lecture Notes (2005), University of Oxford. Davidge, R.W., Mechanical Behavior of Ceramics, Cambridge Solid State Science Series, (1979) Demaid, Adrian, Fail Safe, Open University (2004) Green, D., An Introduction to the Mechanical Properties of Ceramics, Cambridge Solid State Science Series, Eds. Clarke, D.R., Suresh, S., Ward, I.M. (1998) Tipper, Constance Fligg (1962). The brittle fracture story. Cambridge U.P. Lawn, B.R., Fracture of Brittle Solids, Cambridge Solid State Science Series, 2nd Edn. (1993) Farahmand, B., Bockrath, G., and Glassco, J. (1997) Fatigue and Fracture Mechanics of High-Risk Parts, Chapman & Hall. ISBN 978-0-412-12991-9. Chen, X., Mai, Y.-W., Fracture Mechanics of Electromagnetic Materials: Nonlinear Field Theory and Applications, Imperial College Press, (2012) A.N. Gent, W.V. Mars, In: James E. Mark, Burak Erman and Mike Roland, Editor(s), Chapter 10 – Strength of Elastomers, The Science and Technology of Rubber, Fourth edition, Academic Press, Boston, 2013, pp. 473–516, ISBN 9780123945846, 10.1016/B978-0-12-394584-6.00010-8 Zehnder, Alan. Fracture Mechanics, SpringerLink, (2012).
A history of widespread pain lasting more than three months – affecting all four quadrants of the body, i.e., both sides and above and below the waist. Tender points – there are 18 designated possible tender points (although a person with the disorder may feel pain in other areas as well). The ACR criteria for the classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis, but have later become the de facto diagnostic criteria in the clinical setting. A controversial study was done by a legal team looking to prove their client's disability based primarily on tender points, and their widespread presence in non-litigious communities prompted the lead author of the ACR criteria to question the usefulness of tender points in diagnosis. Use of control points has been used to cast doubt on whether a person has fibromyalgia, and to claim the person is malingering. In 2010, the American College of Rheumatology approved provisional revised diagnostic criteria for fibromyalgia that eliminated the 1990 criteria's reliance on tender point testing. The revised criteria used a widespread pain index (WPI) and symptom severity scale (SSS) in place of tender point testing under the 1990 criteria. The WPI counts up to 19 general body areas in which the person has experienced pain in the preceding week. The SSS rates the severity of the person's fatigue, unrefreshed waking, cognitive symptoms, and general somatic symptoms, each on a scale from 0 to 3, for a composite score ranging from 0 to 12.
obtained in this way are qualitatively accurate for a number of simple gases. Slightly more sophisticated models, such as the Lennard-Jones potential, or the more flexible Mie potential, may provide better agreement with experiments, but only at the cost of a more opaque dependence on temperature. A further advantage of these more complex interaction potentials is that they can be used to develop accurate models for a wide variety of properties using the same potential parameters. In situations where little experimental data is available, this makes it possible to obtain model parameters from fitting to properties such as pure-fluid vapour-liquid equilibria, before using the parameters thus obtained to predict the viscosities of interest with reasonable accuracy. In some systems, the assumption of spherical symmetry must be abandoned, as is the case for vapors with highly polar molecules like H2O. In these cases, the Chapman–Enskog analysis is significantly more complicated.
Sources: en.wikipedia.org
== Practical application == In a hydraulic engineering application, it is typical for the volumetric flow Q within a pipe (that is, its productivity) and the head loss per unit length S (the concomitant power consumption) to be the critical important factors. The practical consequence is that, for a fixed volumetric flow rate Q, head loss S decreases with the inverse fifth power of the pipe diameter, D. Doubling the diameter of a pipe of a given schedule (say, ANSI schedule 40) roughly doubles the amount of material required per unit length and thus its installed cost. Meanwhile, the head loss is decreased by a factor of 32 (about a 97% reduction). Thus the energy consumed in moving a given volumetric flow of the fluid is cut down dramatically for a modest increase in capital cost.
The Constitution of Canada is the supreme law of the country and consists of written text and unwritten conventions. The Constitution Act, 1867 (known as the British North America Act, 1867 prior to 1982), affirmed governance based on parliamentary precedent and divided powers between the federal and provincial governments. The Statute of Westminster, 1931, granted full autonomy, and the Constitution Act, 1982, ended all legislative ties to Britain, as well as adding a constitutional amending formula and the Canadian Charter of Rights and Freedoms. The Charter guarantees basic rights and freedoms that usually cannot be overridden by any government; a notwithstanding clause allows Parliament and the provincial legislatures to override certain sections of the Charter for a period of five years.
There are many forms in which herbs can be administered, the most common of which is a liquid consumed as a herbal tea or a (possibly diluted) plant extract. Herbal teas, or tisanes, are the resultant liquid of extracting herbs into water, though they are made in a few different ways. Infusions are hot water extracts of herbs, such as chamomile or mint, through steeping. Decoctions are the long-term boiled extracts, usually of harder substances like roots or bark. Maceration is the cold infusion of plants with high mucilage-content, such as sage or thyme. To make macerates, plants are chopped and added to cold water. They are left to stand for 7 to 12 hours (depending on the herb used). For most macerates, 10 hours is used. Tinctures are alcoholic extracts of herbs, which are generally stronger than herbal teas. Tinctures are usually obtained by combining pure ethanol (or a mixture of pure ethanol with water) with the herb. A completed tincture has an ethanol percentage of at least 25% (sometimes up to 90%). Non-alcoholic tinctures can be made with glycerin, but it is believed to be less absorbed by the body than alcohol based tinctures and has a shorter shelf life. Herbal wine and elixirs are alcoholic extracts of herbs, usually with an ethanol percentage of 12–38%. Extracts include liquid extracts, dry extracts, and nebulisates. Liquid extracts are liquids with a lower ethanol percentage than tinctures. They are usually made by vacuum distilling tinctures. Dry extracts are extracts of plant material that are evaporated into a dry mass.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.